Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda by Ngcobo, N.J. et al.
13       January 2019, Vol. 109, No. 1
IN PRACTICE
Cervical cancer is a public health scourge that affects more than half 
a million women globally, more than half of whom die of the disease 
every year.[1] Low- and middle-income countries (LMICs), especially 
those in sub-Saharan Africa (SSA), bear the greatest burden of 
cervical cancer. Malawi, Mozambique and Comoros have the highest 
incidence of the disease in the world (75.9, 65.0 and 61.3 per 100 000 
women, respectively). This is in contrast to European countries, such 
as Germany, France and Switzerland, which have an incidence of 8.2, 
6.8 and 3.6 per 100 000 women, respectively. SSA is home to 10.5% 
of the global population of women aged ≥15 years; yet, the region 
accounts for 21.6% and 17.7% of the global burden of cervical cancer 
deaths and cases, respectively.[1] 
In South Africa (SA), cervical cancer is the second most common 
cancer that occurs in women and the leading cause of cancer deaths 
among women aged 15 - 44 years, with an estimated annual incidence 
of 7 735 cases and 4 248 deaths a year.[2] Given the high incidence 
of HIV infection, which predisposes women to cervical cancer, and 
the low uptake of cervical cancer screening, the incidence of and 
mortality from cervical cancer in SSA and SA can be expected to rise 
in the absence of primary prevention.[3]
Infection with high-risk types of human papillomavirus (HPV) 
is the cause of cervical cancer, which can be prevented by HPV 
vaccination.[1] The latter has been demonstrated to be safe and highly 
effective, providing up to 98.2% protection against specific high-risk 
strains of HPV.[4-6] HPV vaccines have been available and used in 
several LMICs and high-income countries (HICs) for more than 
a decade. In SA, the bivalent and quadrivalent HPV vaccines have 
been available in the private sector since 2008. In 2014, a school-
based HPV vaccination programme was introduced, with 2 doses 
(6 months apart, administered during 1-month campaigns) of the 
bivalent HPV vaccine offered free of charge to grade 4 girls aged ≥9 years 
in public sector schools.[7] 
Human papillomavirus vaccination 
uptake and hesitancy 
Uptake of the HPV vaccine through the school-based programme 
in SA has been reported to be fairly good, with 85% coverage for 
the first dose in 2014 that targeted about 500 000 female learners.[7,8] 
Subsequent performance has been reported as numbers only and 
has not been converted to percentages. The reported number of 
vaccinated learners for 2014 - 2016 indicates a significant decrease 
between the first and second doses, which amounts to a decrease 
of 21.4% in 2014 and 26.0% in 2016. Furthermore, the study 
commissioned by the National Department of Health (NDoH) to 
assess the first round of the 2014 campaign reported pockets of low 
HPV vaccination coverage, which in two sub-districts were only 40% 
and 43%.[7]      
Suboptimal uptake of HPV vaccination is not unique to areas in 
SA, but remains a serious challenge worldwide. For example, a recent 
meta-analysis of data from 79 studies in 15 countries, including 
>840 000 parents, found the overall parental uptake of ≥1 doses of 
HPV vaccines for their children to be 41.5%.[9] In 2016 in the USA, 
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the ≥1-dose HPV vaccination coverage among teens was 60.4% 
(65.1% for females; 56.0% for males), which was an improvement on 
previous years.[10] Coverage rates are also reported to vary greatly by 
region.[11]
Reasons for poor uptake of HPV vaccination are multifactorial. 
Supply-related factors, such as cost and unavailability of the vaccines; 
inadequate financing mechanisms; poor health system capabilities for 
vaccination; vaccine storage and cold-chain constraints; poor access 
to healthcare; limited and missed vaccination opportunities; and 
low prioritisation of adolescent health, are important contributors 
to suboptimal HPV vaccination uptake, particularly in SSA.[12-14] 
However, vaccine hesitancy may be an important additional factor 
in the low uptake of HPV vaccination for school-based programmes 
that are designed to eliminate most of these obstacles. 
According to the World Health Organization’s Strategic Advisory 
Group of Experts on Immunization (SAGE) Working Group on 
Vaccine Hesitancy, vaccine hesitancy refers to: ‘delays in acceptance 
or refusal of vaccination despite availability of vaccination services.’[15] 
Vaccine hesitancy is known to vary across time, place and vaccines, 
and is believed to be influenced by confidence, complacency, 
convenience, risk calculation and collective responsibility.[15,16] 
Vaccine-hesitant individuals range from those who may accept 
vaccination even when not fully convinced, to those who refuse 
vaccination because they have doubts regarding the necessity or 
safety of vaccines.[15]
The phenomenon of vaccine hesitancy in relation to all vaccination 
programmes, and specifically to HPV vaccination, has been described 
and studied extensively in HICs. Evidence from these countries 
suggests that hesitancy might be higher than for other childhood 
vaccines.[17,18] These studies have identified the following as key issues 
underpinning HPV vaccination hesitancy: trust and safety concerns; 
lack of knowledge regarding the disease and vaccines among the 
targeted population, parents and healthcare workers (HCWs); and 
influence of peers and the community.[18-21] Moreover, research has 
shown that HCWs’ recommendations are critical for HPV vaccination 
acceptance and uptake. For example, a US study found that, despite 
clear guidelines, many HCWs did not routinely recommend HPV 
vaccination.[22] Importantly, studies have reported that some HCWs are 
hesitant and fail to make the recommendation at a critical time, when 
parents need encouragement, clarity and open discussion.[20,22]
It is, however, unclear whether these findings can be generalised 
to SA and other SSA countries, given that vaccine hesitancy is 
thought to be highly variable and context specific.[9] Research on 
HPV vaccine hesitancy in SA is limited. Prior to the introduction 
of the school-based HPV vaccination programme in 2014, various 
studies explored knowledge, attitudes and beliefs regarding HPV 
and cervical cancer, as well as knowledge and acceptance of 
the HPV vaccine.[23-26] A consistent finding across these studies 
was that knowledge and understanding of cervical cancer, the 
relationship between HPV and cervical cancer, and the purpose of 
HPV vaccination were low. The studies also revealed that parents 
might have various concerns regarding the HPV vaccine, including 
its safety and efficacy and its short- and long-term side-effects, 
and that HPV vaccination may encourage risky adolescent sexual 
behaviour. Moreover, the Vaccine and Cervical Cancer Screen 
(VACCS) project, a pilot school-based vaccination programme 
conducted in 19 primary schools in the Western Cape and Gauteng 
provinces prior to the national programme roll-out, indicated that 
suboptimal coverage was predominantly due to lack of parental 
consent.[27,28] The project found that vaccine uptake among girls 
whose caregivers attended information evenings, which included 
addressing safety concerns, was significantly higher (~90%) than 
among girls whose caregivers did not attend (~50%). Parental 
concerns about safety may be linked to negative social media 
coverage of the HPV vaccine. This notion is supported by the 
NDoH-commissioned post-introduction study, where some key 
informants reported that HCWs were ‘nervous’ about using the 
HPV vaccine, and that parental consent was negatively affected in 
areas where negative sentiments about the vaccine were shared on 
social media.[7] Furthermore, anecdotal reports indicated refusal 
by some parents to give consent, including messages such as ‘Do 
not touch my child’ on the consent form (National EPI Manager – 
personal communication, 30 March 2015). 
Being a school-based programme, issues relating to communication 
and social mobilisation for the HPV vaccination programme should 
include various stakeholders, including the Department of Basic 
Education (DoE), specifically the educators, school governing 
bodies and parent associations. These and other community-based 
organisations should be sensitised to and informed on HPV as the 
cause of cervical cancer, and the benefits of HPV vaccination. Delany-
Moretlwe et al.[7] recommended that the DoE should play a more 
prominent role in communication and social mobilisation to increase 
demand for HPV vaccination. This is an important recommendation, 
considering that the DoE has ongoing contact and collaboration with 
these stakeholders, while the NDoH does not. It may go a long way 
towards strengthening the role of educators in promoting the vaccine, 
and ameliorate the potential threat posed by educators who may be 
hesitant to recommend and advocate HPV vaccination.
Research agenda and policy issues
The limited research on and context-specific issues of the HPV 
vaccination programme in SA point to a need for increased research 
on the potential existence, nature and causes of vaccine hesitancy 
in this programme. The setting and circumstances are different 
to many of those in HICs, and therefore unique challenges and 
concerns might exist. For example, the programme does not include 
private schools and is not available at public healthcare facilities. 
This may be a source of concern and undermine trust, as some may 
question the NDoH’s motive for HPV vaccination in public schools. 
Furthermore, being grade based, the programme excludes a large 
number of pre-adolescent, adolescent and young women who are 
eligible for and would benefit from the vaccine. This includes a 
large population of learners attending public and private schools. 
Moreover, there is no readily available information on the uptake 
of the HPV vaccine in the private sector. These issues, and their 
possible negative impact on the prevalence of vaccine hesitancy, 
need to be further researched in SA. 
More specifically, research areas that need to be addressed in SA, 
and potentially other LMICs, are the following: 
• Extent of HPV vaccine hesitancy in the public sector among 
parents of targeted girls and those eligible for the national school-
based HPV vaccination programme. 
• Reasons behind the high drop-out rate between the first and 
second doses of HPV vaccine in this programme. 
• Knowledge, beliefs, attitudes and practices of girls and boys (in the 
general population) who are eligible for the HPV vaccine but are 
not targeted by the national programme. 
• HPV vaccination coverage, HPV vaccination hesitancy, reasons for 
non-vaccination, and socio demographic factors related to HPV 
vaccination status in the private sector. 
• The role of public and private HCWs in HPV vaccination uptake 
and the likelihood of HCWs recommending HPV vaccination to 
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the eligible population, especially considering that a significant 
proportion of this population is not targeted by the national 
programme, and many learners in private schools have medical 
insurance and can afford the vaccine.
• The role of educators in promoting HPV vaccination uptake, and 
the existence and extent of HPV vaccine hesitancy among educators.
• The role played by social media in influencing HPV vaccination 
uptake.
• Obtaining consent for HPV vaccination, and weighing the benefits 
and risks of the current approach to obtaining consent to alternative 
approaches used in other parts of the world. 
Although the literature is based on research from HICs, it provides 
LMICs, such as SA, with enough background to develop policies on 
HPV vaccination that can be continuously shaped by evidence from 
local research. There are a number of policy issues that need to be 
addressed, including: 
• A clear policy on HPV vaccination to address the issue of HPV 
vaccination in public and private sectors, clarifying why the 
vaccine is not provided in private schools.
• Communication and social mobilisation for HPV vaccination, 
which are not only focused on parents and girls targeted by the 
programme. Communication should be broad based and widely 
accessible, targeting the public at large, including all parents, 
young pre-adolescents and adolescents who are eligible for HPV 
vaccination. This focus should include learners (girls and boys) in 
private and public sector schools, who are in grade 5 and higher 
and have not received the HPV vaccine.
• The role of the DoE in communicating and advocating the HPV 
vaccination programme.
• Standard operating procedures for HCWs to ensure that there are 
no missed opportunities in recommending and providing the HPV 
vaccine. These HCWs include paediatricians, general practitioners 
and those in school, adolescent and youth health and primary 
healthcare clinics.
• An integrated approach to provision of the HPV vaccine with 
other services, e.g. youth and adolescent health, school health, 
reproductive health, primary healthcare and health promotion. 
Guidelines and policies of these programmes should be adapted to 
allow integration with HPV vaccination. 
• Vaccinology training that results in accreditation of HCWs who 
interact with the targeted population, including training on HPV 
infection, HPV vaccines, cervical cancer and related matters. This 
will allow HCWs to confidently promote vaccines, including the 
HPV vaccine. 
The extent and impact of vaccine hesitancy need to be investigated 
so that focused interventions may be implemented and appropriate 
policies developed and adopted. It is envisaged that addressing these 
research and policy gaps will help to improve uptake of the HPV 
vaccine, overcome HPV vaccination hesitancy and move SA closer 
to attaining the goal of the global vaccine action plan of creating a 
society that values immunisation as a social good and demands it as 
their right and responsibility.[29] 
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